Down another 6% in a week! So will the GSK share price ever recover?
The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...
Malaysiakini8 小时
GSK's respiratory syncytial virus vaccine approved in M'sia
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that the Arexvy vaccine (MAL24086007ARZ) has been approved in Malaysia for respiratory syncytial virus (RSV). RSV is a common respiratory ...
GSK rises Tuesday, still underperforms market
GSK PLC GSK shares inched up 0.20% to £15.31 Tuesday, on what proved to be an all-around favorable trading session for the ...
cilisos.my16 小时
GSK’s Arexvy vaccine for RSV is approved for Malaysian seniors
Arexvy has been approved in Malaysia for RSV (respiratory syncytial virus), for older adults aged 60 and above. The vaccine ...
Pharmabiz2 小时
EMA’s human medicines committee recommends approval of GSK’s single-vial, fully liquid ...
EMA’s human medicines committee recommends approval of GSK’s single-vial, fully liquid presentation of Menveo meningococcal vaccine: London, UK Wednesday, September 25, 2024, ...
Business Insider1 天
Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GB:GSK), Sonova Holding ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on GlaxoSmithKline (GB:GSK – Research Report), Sonova Holding AG (CH:SOON – Research Report) and Corbus Pharmaceuticals ...
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
The trial testing the immune response of co-administration of GSK's blockbuster vaccines, Shingrix and Arexvy, in adults over ...
GSK's experimental herpes vaccine fails to meet main goal in trial
British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main ...
葛兰素史克(GSK.US)“first-in-class”抗体疗法Nucala达到3期临床主要终点
智通财经APP获悉，葛兰素史克 (GSK.US)宣布，其“first-in-class”抗体疗法Nucala（mepolizumab），在治疗成人慢性阻塞性肺病（COPD）患者的3期临床试验MATINEE中获得积极结果。这一试验结果将支持GSK与监管机构讨论，以提交申请扩展Nucala的适应症。
葛兰素史克(GSK.US)哮喘药物有望治疗慢性肺病 或开辟新增长路线
智通财经APP获悉，葛兰素史克 (GSK.US)治疗哮喘的畅销药物Nucala在用于治疗另一种慢性肺部疾病时呈现出积极效果，或为该产品开辟了一条新的增长途径。 Nucala于2015年首次在美国被批准用于治疗严重哮喘，目前是该公司表现最好的药物，去年的销售额为17亿英镑 (22.4亿美元)。
GlaxoSmithKline获TD Cowen维持"持有"评级
TD Cowen维持对GlaxoSmithKline (GSK:LN) (NYSE: GSK)的"持有"评级，目标价保持在1,790.00英镑不变。该公司的立场是在GlaxoSmithKline报告其哮喘药物depemokimab的III期试验结果积极之后做出的，这与关键意见领袖（KOL）预期的约50%哮喘发作减少率一致。这一表现与已获批准的IL-5抑制剂相似。